October 19, 2018 – IBA (Ion Beam Applications S.A.) is sharing how hospitals can secure performance, investment and their future when establishing a proton therapy center as part of its message at the 2018 Annual American Society for Radiotherapy and Oncology (ASTRO) meeting.
When investing in a technology that will last for over 30 years, the selection of the right partner is of critical importance. During the ASTRO meeting, proton therapy practitioners will share their experience securing, installing, and operating a proton therapy center with IBA during open sessions at the IBA booth. Proton therapy is considered one of the most advanced forms of radiation therapy. Here are 3 steps IBA said are important for establishing a proton therapy program:
1. Securing Performance in Proton Therapy
With the longest experience treating patients with ProteusONE installation, Willis-Knighton Cancer Center in Shreveport, La., will showcase its results with the system's open gantry. The optimized workflow of the ProteusONE allows treatment of up to 20 percent more patients than other competitive systems in a record mean time of 16 minutes treatment room time per patient across a wide range of indications. The technology also offers more options for tracking moving tumors.
Terry Wu, Ph.D., chief of physics at Willis-Knighton, will share his experience of over 500 patients treated with system on the IBA booth, #2033, Sunday, Oct. 21st, at 2 p.m. and on Monday Oct. 22, at 12:30 p.m.
2. Securing the Future in Proton Therapy
Beaumont Health Proton Therapy Center in Royal Oak, Mich., is a leading research center conducting advanced research in particle physics and radiation therapy. As part of its long lasting joint R&D program with IBA, Beaumont staff have been pioneers in the development of Proton Arc Therapy. Beaumont will share its first results using Proton Arc Therapy.
Peyman Kabolizadeh, M.D., Ph.D., medical director at Beaumont Health Proton Therapy Center, will share the latest advances on Proton Arc Therapy on Tuesday, Oct. 23, at 12 p.m. at IBA’s booth.
IBA experts will also demonstrate online adaptive treatment and provide previews to visitors to the IBA booth on multiple research projects that are currently under development.
3. Securing Investment in Proton Therapy
The past five installations of the ProteusONE and ProteusPLUS solutions in North America, Europe and Asia have the first treatment room completed in less than 12 months. This allowed customers to begin providing proton therapy to their cancer patients sooner. The availability and reliability of the system also allow for a fast ramp up of patients. Additionally, the open gantry design allows users to easily treat non-coplanar fields in a wide variety of indications.
Beaumont Health Cancer Center recently completed its first year of operation treating more patients than initially projected – more than 100 patients in year one. Beaumont staff will share their experiences using IBA’s ProteusONE and the benefits of its open gantry design.
Craig Stevens, M.D., Ph.D., chair of radiation oncology, Beaumont Health System, will describe his experience in adding proton therapy to the facility on Sunday, Oct. 21, at 12 p.m. at IBA’s booth.
In addition, University of Pennsylvania, one of the earliest adopters of proton therapy with its establishment of the Roberts Proton Therapy Center, has developed and validated a model-based approach to identify patients who will benefit most from proton therapy. Such an approach helps identify the cancer patients who could most benefit from proton therapy. UPENN will share its model and its resulting impact on the treatment of head and neck patients.
Alexander Lin, M.D., medical director at Roberts Proton Therapy Center, will demonstrate his patient selection model on Monday, Oct. 22, at 4 p.m. at IBA’s booth.
Partnering With Market Leaders for Maximum Customer Benefit
IBA continues to expand its collaboration with key technology partners to further integrate its proton therapy solutions with existing radiation oncology systems and equipment. IBA will be showing in its booth how it provides maximum flexibility as well as new development opportunities for new and existing customers.
Earlier this year, IBA and Elekta signed an agreement to develop and offer the broadest single platform for use across all radiation treatment modalities. IBA and Elekta are developing new functionalities specific to proton therapy treatment in Elekta’s Monaco treatment planning system (TPS) and enhancing Mosaiq, Elekta’s industry-leading patient-centric oncology information system (OIS) with the goal to enable clinical pathway-driven adaptive particle therapy. This will offer a seamless experience across modalities for comprehensive radiotherapy departments and further improve patient care.
IBA also has a long-term strategic collaboration with Philips Healthcare. By combining their respective expertise in image guidance and therapy, Philips and IBA continue to co-innovate diagnostic and therapeutic oncology solutions designed to enable more effective and personalized cancer care. The combined portfolio focuses on fast and easy workflow, from imaging through treatment, while maximizing patient comfort and providing a soothing treatment experience.
IBA and RaySearch will present their online adaptive proton therapy workflow where daily optimized plans are created for each individual patient based on cone-beam CT images to preserve the original treatment intent. Both companies are demonstrating RaySearch RayCare, the innovative new oncology information system (OIS) designed to support comprehensive cancer care, and the RayStation workflow and treatment planning system, as well as IBA’s AdaPT Insight imaging platform and AdaPT Deliver treatment delivery. The solution automatically suggests to the care team an adapted treatment plan based on the most up-to-date patient’s anatomy. This workflow offers more accurate treatment plans as well as faster plan adaptation to the benefit of patients. Demonstrations can be booked by visiting either RaySearch's or IBA’s booth.
For more information: https://iba-worldwide.com/
August 09, 2024 
